Currently, the use of immunotherapy-chemotherapy combination approach has been approved for both squamous and non-squamous cell carcinomas, irrespective of PD-1/PD-L1 expression levels [17]. The gene discussed is PDCD1; the disease is squamous cell carcinoma.